Major cardiovascular events after COVID-19 in people with HIV
Raquel Martín-Iguacel(Odense University Hospital), Josep M. Llibre(Badalona Serveis Assistencials), Ana Gonzalez‐Cordón, Işık Somuncu Johansen, Daniel K. Nomah(Universitat Autònoma de Barcelona), Arkaitz Imaz(Bellvitge University Hospital), Beatriz Borjabad(Ajuntament de L’Hospitalet), Jordi Aceitón(Generalitat de Catalunya), David Dalmau Juanola, Peré Domingo(Hospital de Sant Pau), Andreu Bruguera(Badalona Serveis Assistencials), Jordi Casabona(Centro de Estudios Políticos y Constitucionales), José M Miró(Instituto de Salud Carlos III), Laia Arbones Fernandez(Hospital de Mataró), Adrián Curran(Lexington City Schools), Joaquim Peraire(Instituto de Salud Carlos III), Sergio Moreno‐Fornés(Generalitat de Catalunya)
Cited by 2
Related Papers
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
|PLoS Medicine|2013|362
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies
|Cancer|2010|141
Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006|137